CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Authors : Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A Year : 2023 Journal : Lancet Haematol
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions.
Authors : Castelo-Branco L, Morgan G, Prelaj A, Scheffler M, Canhão H, van Meerbeeck JP, Awada A Year : 2023 Journal : ESMO Open
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials.
Authors : Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G Year : 2023 Journal : Ann Oncol
How I treat endocrine-dependent metastatic breast cancer.
Authors : Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A Year : 2023 Journal : ESMO Open
PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer.
Authors : Amato O, Buisseret L, Gebhart G, Plouznikoff N, Larsimont D, Awada A, Piccart M, Aftimos P Year : 2023 Journal : Cold Spring Harb Mol Case Stud